Search / Trial NCT06226571

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Launched by SYNDAX PHARMACEUTICALS · Jan 23, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Sndx 5613 Lysine Specific Methyltransferase 2 A Kmt2 A/Mll Nucleophosmin 1 Npm1 Nucleoporin 98 Nup98 Aml

Description

The Dose Escalation portion of this study will identify the maximum tolerated dose, or if different, the recommended Phase 2 dose of SNDX-5613 to be used in combination with intensive chemotherapy and in maintenance monotherapy following intensive chemotherapy in participants with newly diagnosed AML harboring alterations in KMT2A, NPM1, or NUP98 genes. In the Dose Expansion portion of the study, safety and preliminary efficacy of SNDX-5613 may be explored in expansion cohorts at tolerated dose levels. In both Dose Escalation and Dose Expansion, the treatment period will consist of an ind...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Established, pathologically confirmed diagnosis of AML by World Health Organization 2022 criteria.
  • * Previously untreated AML and eligible to receive intensive chemotherapy.
  • * KMT2Ar, NPM1c, or NUP98r mutations identified by local laboratory prior to the first dose of SNDX-5613.
  • * Eastern Cooperative Oncology Group performance status ≤2 and ≤1 if \>65 years old .
  • * Adequate liver, kidney, and cardiac function.
  • Exclusion Criteria:
  • * Diagnosis of acute promyelocytic leukemia.
  • * Clinically active central nervous system leukemia (blasts detected in cerebrospinal fluid, radiographic or clinical signs and symptoms).
  • * Fridericia's corrected QT interval (QTcF) \>450 milliseconds (average of triplicate), diagnosis or suspicion of Long QT syndrome or family history of Long QT syndrome.
  • * Any gastrointestinal issue of the upper gastrointestinal tract that might affect oral drug absorption or ingestion.
  • * Cirrhosis with a Child-Pugh score of B or C.
  • * Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack.
  • * Hepatitis B, Hepatitis C, or HIV-positive with detectable viral load.
  • * Documented active, uncontrolled infection.
  • * Uncontrolled disseminated intravascular coagulation.
  • * Lactating/breast feeding or pregnant.
  • * Use of prohibited concomitant chemotherapy, radiation therapy, or immunotherapy.
  • * Use of strong CYP3A4 inducers or inhibitors (except for Itraconazole, Ketoconazole, Posaconazole, or Voriconazole).

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for the treatment of cancer and other serious diseases. With a strong focus on developing novel immuno-oncology and epigenetic therapies, Syndax aims to improve patient outcomes through targeted approaches that harness the body's immune system and address key biological pathways in tumor progression. The company is committed to rigorous scientific research and collaboration, driving the development of its pipeline candidates through various phases of clinical trials to bring transformative treatments to patients in need.

Locations

Saint Louis, Missouri, United States

Duarte, California, United States

Houston, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0